Treatment of Children and Adolescents With Growth Failure Associated With Primary IGF-1 Deficiency
Status:
Terminated
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
This is an extension study to Tercica study MS301 (NCT00125164) and is intended to collect
long term safety and efficacy data on the continued use of recombinant human insulin-like
growth factor-1 (rh IGF-1) in children and adolescents treated for primary IGF-1 deficiency
(IGFD). The secondary objective is to use the data collected to learn more about the
relationship of IGF-1 exposure to the promotion of normal growth and pubertal development.